Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants
Por:
Abancó, F, Tarrés-Freixas, F, Lepore, R, Molina-Molina, E, Franco, E, Boreika, R, Pradenas, E, Raïch-Regué, D, Erkizia, I, Clotet, B, Valencia, A, Vergara-Alert, J, Segalés, J, Carrillo, J, Izquierdo-Useros, N, Blanco, J and Trinité, B
Publicada:
28 ene 2026
Resumen:
The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals. Here, we optimized angiotensin-converting enzyme 2 (ACE2)-Fc fusion proteins by combining three engineering steps: in silico mutagenesis of the S protein binding interface to increase affinity, insertion of a flexible linker to improve protein stability and S protein accessibility, and generation of a tetrameric molecule to maximize avidity. Neutralizing activity was tested against a large panel of pre-Omicron and Omicron pseudoviruses and authentic viruses, including JN.1 and KP.2 variants. Optimized ACE2-Fc molecules demonstrated potent neutralizing activity, in the picomolar range, against all SARS-CoV-2 variants. Our molecules displayed similar potency but better resilience when compared to the monoclonal antibody Sipavibart. These findings support ACE2-Fc proteins as robust candidates for next-generation interventions against infection by an evolving SARS-CoV-2.
Filiaciones:
:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
Univ Vic Cent Univ Catalonia UVic UCC, Med & Biomed Sci Program, Vic, Spain
Tarrés-Freixas, F:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
Univ Vic Cent Univ Catalonia UVic UCC, Med & Biomed Sci Program, Vic, Spain
Campus Univ Autonoma Barcelona UAB, Ctr Recerca Sanitat Anim CReSA, Unitat Mixta Invest IRTA UAB Sanitat Anim, Bellaterra, Spain
UAB, Ctr Recerca Sanitat Anim CReSA, Programa Sanitat Anim, IRTA,Campus UAB, Bellaterra, Spain
Lepore, R:
Barcelona Supercomp Ctr BSC, Life Sci Dept, Barcelona, Spain
:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
Boreika, R:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain
Valencia, A:
Barcelona Supercomp Ctr BSC, Life Sci Dept, Barcelona, Spain
Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
Vergara-Alert, J:
Campus Univ Autonoma Barcelona UAB, Ctr Recerca Sanitat Anim CReSA, Unitat Mixta Invest IRTA UAB Sanitat Anim, Bellaterra, Spain
UAB, Ctr Recerca Sanitat Anim CReSA, Programa Sanitat Anim, IRTA,Campus UAB, Bellaterra, Spain
Segalés, J:
Campus Univ Autonoma Barcelona UAB, Ctr Recerca Sanitat Anim CReSA, Unitat Mixta Invest IRTA UAB Sanitat Anim, Bellaterra, Spain
Campus UAB, Fac Vet, Dept Sanitat & Anat Anim, Bellaterra, Spain
Carrillo, J:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain
:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain
:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
Univ Vic Cent Univ Catalonia UVic UCC, Med & Biomed Sci Program, Vic, Spain
Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain
Germans Trias i Pujol Res Inst IGTP, Badalona, Spain
Trinité, B:
IrsiCaixa, Carretera Canyet S-N, Badalona 08916, Spain
Green Submitted
|